🔬 𝗗𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 & 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗘𝗾𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗡𝗮𝗻𝗼𝗧𝗲𝗰𝗵 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 🧬

At DCN Corp® we hope to transform Nano-tech into accessible and life-enhancing diagnostic platform technologies.

Our proprietary platform technology is validated to TRL 3, and protected by a robust hybrid IP strategy.

- What We Do:
We’ve developed a useful Surface Plasmon Resonance (SPR) process technology, designed for next-gen diagnostics.

It enables:
- Real-time biological insights
- Quantitative severity analysis
- Compatibility with Raman & Infrared instruments

This innovation should evolve into a scalable handheld bio-kit for early detection and precision diagnostics.

- Our Mission:
To pioneer Nano-tech applications that positively impact humanity. Through rigorous science and inclusive design, we aim to democratise diagnostics for global health equity.

- Our Vision:
We all know someone affected by cancer, cardiovascular disease, or other life-altering conditions. These illnesses respond better to early, accurate detection. Therefore, our vision is to create a handheld diagnostic bio-kit that supports this goal - aligned with future at-home diagnostics requirements.

Supported by research - Crosby et al. (2022), Science Journal: “Early Detection of Cancer”.

- Market & Impact Potential:
- Global diagnostics market: £100B+
- SPR-based tools projected to grow 18% CAGR (2024–2030)
- Early detection improves survival rates by up to 70%

- What We’re Looking For:
To bring this vision to life, we’re actively seeking:
- R&D & Technical Collaborations
- Financial Partnerships
- Design & Engineering Support
- Next Milestone: Applying nano-tech to plastic polymer plates to increase bio-sensitivity.
- Fundraising Now: Seed round of £500K+ ($677K+)

📩 Let’s Shape the Future of Diagnostics Together

If you're an investor, scientist, or industrial partner, request our Executive Summary today.

📅 Book a 30-min Intro call: calendly.com/dcncorp-info/30min

DCN Corp®

Org chart

Teams

Offices

DCN Corp®

Org chart

Teams

Offices

Related companies